Hypomethylating agent/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia

被引：4
|
作者：
Jamy, Omer [1 ]
Lin, Karen [2 ]
Worth, Sarah [1 ]
Bachiashvili, Kimo [1 ]
Rangaraju, Sravanti [1 ]
Vachhani, Pankit [1 ]
Bhatia, Ravi [1 ]
机构：
[1] Univ Alabama Birmingham, Dept Med, Div Hematol & Oncol, Birmingham, AL 35294 USA
[2] Grandview Med Ctr, Dept Med, Birmingham, AL USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 198卷 / 03期
关键词：
VENETOCLAX;
D O I：
10.1111/bjh.18229
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E35 / E37
页数：3
相关论文
共 50 条
  • [21] Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center
    Tenold, Matthew E.
    Moskoff, Benjamin N.
    Benjamin, David J.
    Hoeg, Rasmus T.
    Rosenberg, Aaron S.
    Abedi, Mehrdad
    Tuscano, Joseph M.
    Jonas, Brian A.
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [22] Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
    Aldoss, Ibrahim
    Yang, Dongyun
    Pillai, Raju
    Sanchez, James F.
    Mei, Matthew
    Aribi, Ahmed
    Ali, Haris
    Sandhu, Karamjeet
    Al Malki, Monzr M.
    Salhotra, Amandeep
    Khaled, Samer
    Sun, Weili
    O'Donnell, Margaret
    Snyder, David
    Nakamura, Ryotaro
    Stein, Anthony S.
    Forman, Stephen J.
    Marcucci, Guido
    Pullarkat, Vinod
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (10) : E253 - E255
  • [23] Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia
    Graveno, Molly E.
    Carulli, Alison
    Freyer, Craig W.
    Mangan, Brendan L.
    Nietupski, Robert
    Loren, Alison W.
    Frey, Noelle, V
    Porter, David L.
    Gill, Saar, I
    Hexner, Elizabeth O.
    Luger, Selina M.
    Martin, Mary Ellen
    McCurdy, Shannon R.
    Perl, Alexander E.
    Babushok, Daria, V
    Pratz, Keith W.
    LEUKEMIA & LYMPHOMA, 2022, 63 (07) : 1645 - 1650
  • [24] Molecular Predictors of Response and Survival in Patients with Relapsed/Refractory Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy
    Johnson, Isla McKerrow
    Ilyas, Rimal
    McCullough, Kristen
    Al-Kali, Aref
    Alkhateeb, Hassan B.
    Begna, Kebede
    Mangaonkar, Abhishek A.
    Litzow, Mark R.
    Hogan, William J.
    Shah, Mithun, V
    Patnaik, Mrinal M.
    Pardanani, Animesh
    Tefferi, Ayalew
    Gangat, Naseema
    BLOOD, 2022, 140 : 3233 - 3234
  • [25] The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients
    Jiang, Xuejie
    Wang, Zhixiang
    Ding, Bingjie
    Yin, Changxin
    Zhong, Qingxiu
    Carter, Bing Z.
    Yu, Guopan
    Jiang, Ling
    Ye, Jieyu
    Dai, Min
    Zhang, Yu
    Liang, Shuang
    Zhao, Qingxia
    Liu, Qifa
    Meng, Fanyi
    ONCOTARGET, 2015, 6 (32) : 33612 - 33622
  • [26] Ten-Day Decitabine with Venetoclax Versus Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia: A Propensity Score Matched Analysis
    Maiti, Abhishek
    DiNardo, Courtney D.
    Kadia, Tapan M.
    Jabbour, Elias
    Rausch, Caitlin R.
    Daver, Naval
    Borthakur, Gautam
    Pemmaraju, Naveen
    Short, Nicholas J.
    Yilmaz, Musa
    Alvarado, Yesid
    Montalbano, Kathryn S.
    Wade, Allison
    Maduike, Rita
    Guerrero, Julio A.
    Vaughan, Kenneth
    Bivins, Carol A.
    Pierce, Sherry A.
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Konopleva, Marina
    BLOOD, 2020, 136
  • [27] The Hypomethylating Agent Decitabine Prior to Chemotherapy Improves the Therapy Efficacy in Refractory/Relapsed Acute Myeloid Leukemia Patients
    Jiang, Xuejie
    Wang, Zhixiang
    Yin, Changxin
    Yu, Guopan
    Ye, Jieyu
    Zhang, Yu
    Fan, Zhiping
    Xu, Dan
    Liu, Xiaoli
    Feng, Ru
    Xu, Bing
    Sun, Jing
    Liu, Qifa
    Carter, Bing Z.
    Meng, Fanyi
    BLOOD, 2015, 126 (23)
  • [28] A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML)
    Park, Silvia
    Kwag, Daehun
    Kim, Tong Yoon
    Lee, Jong Hyuk
    Lee, Joon Yeop
    Min, Gi June
    Park, Sung Soo
    Yahng, Seung-Ah
    Jeon, Young-Woo
    Shin, Seung-Hwan
    Yoon, Jae-Ho
    Lee, Sung-Eun
    Cho, Byung Sik
    Eom, Ki-Seong
    Kim, Yoo-Jin
    Lee, Seok
    Min, Chang-Ki
    Cho, Seok-Goo
    Lee, Jong Wook
    Kim, Hee-Je
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
  • [29] Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia
    Thomas, DA
    Estey, E
    Giles, FJ
    Faderl, S
    Cortes, J
    Keating, M
    O'Brien, S
    Albitar, M
    Kantarjian, H
    BRITISH JOURNAL OF HAEMATOLOGY, 2003, 123 (03) : 436 - 441
  • [30] Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia
    Weng, Guangyang
    Zhang, Yu
    Yu, Guopan
    Luo, Tingyue
    Yu, Sijian
    Xu, Na
    Sun, Zhiqiang
    Lin, Dongjun
    Deng, Lan
    Liang, Xinquan
    Xiao, Jie
    Zhang, Hongyu
    Guo, Ziwen
    Shao, Ruoyang
    Du, Xin
    Jin, Hua
    Liu, Qifa
    JOURNAL OF INTERNAL MEDICINE, 2023, 293 (03) : 329 - 339
12345